The aim of this study was to determine which antibiotic combinations are appropriate for 38 culture-negative hematogenous vertebral osteomyelitis (HVO), based on the antibiotic-39 susceptibility pattern of organisms isolated from cases of culture-proven HVO. We conducted 40 a retrospective chart review of adult patients with microbiologically proven HVO in five 41 tertiary-care hospitals over a 7-year period. The appropriateness of empiric antibiotic 42 regimens was assessed based on the antibiotic susceptibility profiles of isolated bacteria. In 43 total, 358 cases of microbiologically proven HVO were identified. The main causative 44 pathogens identified were methicillin-susceptible Staphylococcus aureus (33.5%), followed 45 by methicillin-resistant S. aureus (MRSA) (24.9%), aerobic gram-negative bacteria (21.8%), 46
7 all other species, strains were considered susceptible if they showed susceptibility to at least 134 one of the antimicrobial agent combinations. 135
136

Definitions 137
HVO was classified as community-acquired or healthcare-associated HVO according to 138 published criteria (5). Healthcare-associated HVO was defined as (i) onset of symptoms after 139 1 month of hospitalization with no evidence of vertebral osteomyelitis at admission, (ii) 140 hospital admission within 6 months before symptom onset, or (iii) ambulatory diagnostic or 141 therapeutic manipulations within 6 months before symptom onset (long-term central venous 142 catheter use, arteriovenous fistula for hemodialysis, invasive intravascular techniques, 143 urological, gynecological or digestive procedures, and cutaneous manipulations). Cases that 144
did not meet any of the above criteria were classified as community-acquired HVO (5). 145
146
Statistical analyses 147
Categorical variables are expressed as numbers and percentages and were compared by χ2 or 148
Fisher's exact test. Continuous variables are expressed as medians and interquartile ranges 149 and were compared using Mann-Whitney U test. All statistical tests were two-tailed, and P ≤ 150 0.05 was considered to indicate statistical significance. All statistical analyses were 151 performed using SPSS for Windows software (ver. 18.0; SPSS, Inc., Chicago, IL). 152 153 8
RESULTS 154
In total, 370 patients with microbiologically proven HVO were identified during the study 155 period. Of the 370 cases, 12 were excluded due to incomplete medical records and 358 were 156 included in the final analysis. 157 158
Patients' characteristics 159
The demographic and baseline characteristics of the patients are displayed in Table 1 . The 160 median age of the cohort was 65 years, and 186 (52.0%) were males. The most common 161 underlying condition was diabetes (29.3%), followed by liver cirrhosis (9.2%) and 162 malignancy (8.7%). According to the predefined criteria, 225 (62.8%) cases were 163 community-acquired HVO and 133 (37.2%) were healthcare-associated HVO. 164
165
Microbiological findings 166
Of the 358 cases with microbiologically proven HVO, 93 (26.0%) Table 2 ). Of 78 aerobic gram-negative 171 bacteria, Enterobacteriaceae was responsible for 69 (88.5%) cases and other gram-negative 172 bacteria for 9 (11.5%) cases. Of 42 Streptococcus species, viridans group streptococci were 173 the most frequently isolated organisms (50.0%), followed by Streptococcus agalactiae 174 (35.7%), and S. pneumoniae (9.5%). CoNS, Enterococcus species, and anaerobes accounted 175 for 2.8%, 2.8%, and 1.4%, respectively. 176
There were some differences in the proportions of pathogens between community-acquired 177 HVO and healthcare-associated HVO. MRSA was more frequent in healthcare-associated9 HVO than in community-acquired HVO (43.6% vs. 13.8%; P < 0.001), but MSSA was more 179 frequent in community-acquired HVO than in healthcare-associated HVO (44.0% vs. 13.8%; 180 P < 0.001). Streptococcus species were more frequent in community-acquired cases than in 181 healthcare-associated cases (16.0% vs. 4.5%; P = 0.001). We evaluated the susceptibility profiles of microorganisms causing HVO and assessed the 211 appropriateness of several empiric antibiotic regimens for culture-negative HVO. Our data 212
showed that oral antibiotic combinations may be suboptimal for empiric treatment of culture-213 negative HVO, and should be used after definitively ruling out healthcare-associated HVO. 214
Vancomycin combined with fluoroquinolones or broad-spectrum cephalosporins were 215 appropriate for most cases of community-acquired and healthcare-associated HVO. 216
In this study, the most frequently isolated organism was S. aureus, with 43% being MRSA. 217
In recent years, the prevalence of MRSA among S. aureus vertebral osteomyelitis has been 218 reported to be 40-57% (11, (14) (15) (16) . The resistance rate of Enterobacteriaceae isolates to 219 ciprofloxacin was 26% in this study, compared to 31% and 38% in two recent studies 220 conducted in South Korea and France, respectively (17, 18). Vertebral osteomyelitis caused 221 by antibiotic-resistant organisms may have a higher risk of treatment failure (16, 19, 20) . 222
Indeed, patients with MRSA vertebral osteomyelitis reportedly have a 4-5-fold higher risk of 223 recurrence than those with MSSA vertebral osteomyelitis (16, 19) . In a study of patients with 224 gram-negative bacterial HVO, half of those infected with fluoroquinolone-resistant strains 225 experienced recurrence after 4-8 weeks of antibiotic treatment (20). Thus, the increasing 226 incidence of antibiotic resistance in causative pathogens of vertebral osteomyelitis should be 227 considered when selecting an empiric antibiotic regimen for culture-negative HVO. 228
Fluoroquinolone-based regimens have high oral bioavailability and good bone penetration, 229 allow an early switch to oral therapy, and appear to be the best option for empiric treatment of 230 culture-negative vertebral osteomyelitis (8, 21) . Two previous studies showed that empiric 231 treatment with levofloxacin plus rifampin had overall response rates of 78% (3) and 84% 232 (22). In another study, empiric treatment with ciprofloxacin plus amoxicillin-clavulanate had 233 an overall response rate of 82% (23). All three studies were conducted in an epidemiologic12 setting featuring a low prevalence of MRSA (3, 22, 23) , and the appropriateness of these 235 regimens in high-MRSA-prevalence settings was not evaluated. In the current study, based on 236 the susceptibility profiles of isolated bacteria, these combination regimens were appropriate 237 in 74% and 67% of cases, respectively. We also found that levofloxacin plus clindamycin 238 exhibited activity against 71% of causative organisms of HVO. Fluoroquinolone plus 239 clindamycin is suggested for the treatment of culture-negative vertebral osteomyelitis by 240
British guidelines (4), but clinical data on this regimen in this setting are limited. The marked 241 inappropriateness of fluoroquinolone-based regimens in the current study may be due to the 242 high prevalence of MRSA (25%). Almost half of our MRSA isolates were resistant to 243 fluoroquinolones, and the resistance rates to their companion drugs, such as rifampin and 244 clindamycin, were high (22% and 58%, respectively). Recently, Desoutter et al. reported the 245 susceptibility patterns of microorganisms isolated from 101 cases of non-bacteremic vertebral 246 osteomyelitis by percutaneous needle biopsy (17). According to the antibiotic susceptibility 247 profiles, fluoroquinolone-based regimens were appropriate in 58-77% of cases (17). In 248 contrast to our study, MRSA was responsible for only one case of vertebral osteomyelitis, but 249
CoNS was the most frequent isolate, with 20% of isolates being resistant to fluoroquinolones 250 (17). Also, the almost 40% rate of fluoroquinolone resistance in Enterobacteriaceae isolates 251 contributed to the relatively low suitability of fluoroquinolone-based regimens (17). To 252 minimize the risk of microbiological failure, we reassessed the suitability of empiric 253 regimens in community-acquired and healthcare-associated cases. These analyses indicated 254 that fluoroquinolone-based regimens were appropriate in up to 86% of community-acquired 255 HVO cases, but in only 38-53% of healthcare-associated HVO cases. Thus, based on current 256 data, as well as previous clinical experience (3, 22, 23), fluoroquinolone-based regimens may 257 be useful for empiric treatment of community-acquired HVO, but they should not be used for 258 healthcare-associated HVO.
13
In this study, vancomycin plus ciprofloxacin or broad-spectrum cephalosporins were 260 appropriate in most cases of community-acquired and healthcare-associated HVO. Although 261
ESBL-producing Enterobacteriaceae accounted for 9% of the Enterobacteriaceae isolates, it 262
accounted for only 2% of all causative organisms. The prevalence of anaerobes was 1% in 263 this work, and up to 4% in two recent studies (3, 21). Thus, antibiotic coverage of such rare 264 organisms (with carbapenems or metronidazole) may be not required initially, and should be 265 limited to patients who show no clinical improvement after empiric treatment and negative 266 results of repeated biopsies. As a companion drug to vancomycin, fluoroquinolones and 267 broad-spectrum cephalosporins were similarly effective in healthcare-associated HVO. 268
Taking into consideration the bone penetration of antibiotics (24), we prefer fluoroquinolones 269 over broad-spectrum cephalosporins as companion drugs to vancomycin. 270 the efficacy of first-generation cephalosporins are required before they can be widely used for 284 culture-negative vertebral osteomyelitis. 285
Our study had several limitations. First, some cases lacked antibiotic susceptibility test 286 results and so exclusion of these cases may have introduced bias. Second, we assessed the 287 appropriateness of empiric antibiotic regimens for culture-negative HVO based on the data of 288 organisms isolated from microbiologically proven cases. However, culture-negative vertebral 289 osteomyelitis may be more closely related to cases caused by low-virulence pathogens, such 290 streptococci and CoNS (3, 29) , and the prevalence of these organisms may have been 291 underestimated in our analysis. In this study, Streptococcus species were less likely to be 292 detected in blood cultures than S. aureus (62% vs. 82%). Finally, this study included only 293 patients with HVO, and so our findings should not be extrapolated to cases of post-surgical 294 vertebral osteomyelitis, in which CoNS and antibiotic-resistant organisms may be more 295
common. 296
In summary, in a setting in which MRSA is a frequent causative organism of HVO, 297 cautious selection of empiric antibiotics is required. Oral empiric antibiotic combinations 298 may be suboptimal for culture-negative HVO, and should be used only in 299 community-acquired cases. Vancomycin combined with fluoroquinolone or a broad-spectrum 300 cephalosporin is appropriate in most cases of HVO. The clinical efficacy of empiric antibiotic 301 regimens for culture-negative HVO reported here should be verified in further studies. 
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